Mark Berman,
Past President, American Academy of Cosmetic Surgery; Medical Director,
California Stem Cell Treatment Center
Mark practices cosmetic surgery in Beverly Hills, California. He was the 2010 President of the American Academy of Cosmetic Surgery. In 2011, he and Elliot Lander, MD, started the California Stem Cell Treatment Center and later co-founded the Cell Surgical Network (CSN) advancing this work among colleagues throughout the world. He and his wife, Saralee, have a son, Sean, who recently graduated from Amherst College and currently is a grad-student and quarterback at Louisiana Tech University.
From Cosmetics to Therapeutics: Establishing a Compliant Regenerative Medical Surgical Organization
Monday, 22 April 2013 at 16:00
Add to Calendar ▼2013-04-22 16:00:002013-04-22 17:00:00Europe/LondonFrom Cosmetics to Therapeutics: Establishing a Compliant Regenerative Medical Surgical OrganizationClinical Translation of Stem Cells Summit in Palm Springs, CA, USAPalm Springs, CA, USASELECTBIOenquiries@selectbiosciences.com
We believe there is immediate benefit to be gained by the use of Adipose Derived Stromal Vascular Fraction (ADSVF or just SVF) that is known to contain Adipose Derived Stem Cells (ADSC) a known form of Mesenchymal Stem Cells (MSC). While major universities and pharmaceutical companies clamor to unlock the magic within stem cells, they contend we remain 5 to 10 years away from clinical applications. In the meantime, enough anecdotal and scientific evidence suggests that stem cells can be utilized now for effective therapy of a multitude of inflammatory and degenerative conditions. Following the initial lead from the Plastic Surgery community, we have developed a multidisciplinary approach to utilizing current technology to produce and deploy SVF for the immediate treatments of a variety of inflammatory and degenerative conditions. While we have also developed a completely closed surgical procedure, we have remained cognizant of the FDA regulations (21 CFR part 1271) for Human Cells, Tissues and Products. The primary objective of initial trials are aimed to determine the relative degree of risk that exists when harvesting fat and deploying autologous SVF derived from it with our particular equipment and protocol. The secondary objective remains to obtain data as to possible efficacy.
Add to Calendar ▼2013-04-22 00:00:002013-04-23 00:00:00Europe/LondonClinical Translation of Stem Cells SummitClinical Translation of Stem Cells Summit in Palm Springs, CA, USAPalm Springs, CA, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2013-04-22 16:00:002013-04-22 17:00:00Europe/LondonFrom Cosmetics to Therapeutics: Establishing a Compliant Regenerative Medical Surgical OrganizationClinical Translation of Stem Cells Summit in Palm Springs, CA, USAPalm Springs, CA, USASELECTBIOenquiries@selectbiosciences.com
